In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

Two recent tools in the battle for weight loss have been showing incredible results: Semaglutide and Tirzepatide ... and body fat, and even helps people sleep better at night.